Author

A. Font-Tello

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Organism:human· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2

Frequent Co-Authors

H. W. Long· 3 shared K. Lim· 3 shared P. Cejas· 3 shared Y. Xie· 3 shared J.-H. Seo· 2 shared M. Brown· 2 shared M. L. Freedman· 2 shared X. Qiu· 2 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

H. W. Long

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

A. Nardone, X. Qui, A. Feiglin, X. Fu, S. Spisak, A. Feit, G. Cohen Feit, Y. Xie, A. Font-Tello, C. Guarducci, F. Hermida Prado, S. Syamala, K. Lim, M. Pun, M. Cornwell, , R. Jeselsohn

This study identifies a unique chromatin state in invasive lobular breast cancer (ILC) driven by FOXA1-ER axis, leading to tamoxifen resistance and poor outcomes.

bioRxiv · Mar 29, 2022Cancer Biology

FGFR inhibitor mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance

Y. Li, X. Qiu, X. Wang, H. Liu, R. Geck, A. K. Tewari, T. Xiao, A. Font-Tello, K. Lim, J. L. Kristen, M. Morrow, R. Vadhi, P.-L. Kao, A. Jaber, S. Yerrum, , M. Brown

The paper shows that FGFR inhibitors cause SWI/SNF complex dismissal from YAP-dependent enhancers, leading to adaptive resistance in TNBC through epigenetic and metabolic changes.

bioRxiv · Mar 2, 2021Cancer Biology

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer

P. Cejas, Y. Xie, A. Font-Tello, K. Lim, S. Symala, X. Qiu, A. Tewari, N. Shah, H. Nguyen, R. Patel, L. Brown, I. Coleman, W. M. Hackeng, L. Brosens, K. Dreijerink, , H. W. Long

This study identifies two distinct subtypes of neuroendocrine prostate cancer based on neuronal transcription factors and highlights their epigenetic convergence and therapeutic implications.

bioRxiv · Sep 13, 2020Cancer Biology

Predicting master transcription factors from pan-cancer expression data

J. Reddy, M. A. S. Fonseca, R. I. Corona, R. Nameki, F. Segato Dezem, I. A. Klein, H. Chang, D. Chaves-Moreira, L. Afeyan, T. M. Malta, X. Lin, F. Abbasi, A. Font-Tello, T. Sabedot, P. Cejas, , K. Lawrenson

This paper introduces CaCTS, an algorithm that identifies candidate master transcription factors (MTFs) across 34 cancer types using RNA-seq data, revealing novel MTFs and functional groupings.

bioRxiv · Nov 12, 2019Cancer Biology